Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 5/20 | 0.68 |
| ▸ | AURKA | O14965 | 2/20 | 0.68 |
| ▸ | SRC | P12931 | 2/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 3/20 | 0.61 |
| ▸ | HPGD | P15428 | 3/20 | 0.61 |
| ▸ | PDE5A | O76074 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.57 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.57 |
| ▸ | GSK3A | P49840 | 4/20 | 0.57 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.57 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | ABCG2 | Q9UNQ0 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL786402 | 0.93 | GSK3B (0.65) | GSK3BAURKASRCPDE5ASMN1; SMN2 | |
| SCHEMBL786318 | 0.90 | GSK3B (0.62) | GSK3BAURKASRCPDE5ASMN1; SMN2 | |
| SCHEMBL786548 | 0.88 | LATS1 (0.58) | GSK3BAURKASRCPDE5ATGFBR1 | |
| SCHEMBL786173 | 0.88 | PDE5A (0.60) | GSK3BAURKASRCPOLBPDE5A | |
| SCHEMBL786397 | 0.87 | MAPK1 (0.64) | KDM4EALDH1A1POLBHPGDPDE5A | |
| SCHEMBL12653900 | 0.87 | GSK3B (0.56) | GSK3BAURKASRCPDE5ASMN1; SMN2 | |
| SCHEMBL786191 | 0.87 | ABCG2 (0.58) | GSK3BAURKASRCPDE5ASMN1; SMN2 | |
| SCHEMBL12653753 | 0.87 | GSK3B (0.56) | GSK3BAURKASRCPDE5ASMN1; SMN2 | |
| SCHEMBL786621 | 0.87 | CYP1A1 (0.60) | GSK3BAURKASRCPDE5ASMN1; SMN2 | |
| SCHEMBL786160 | 0.86 | GSK3B (0.62) | GSK3BAURKASRCKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7666647-B2 | Inhibitors of GSK-3 and crystal structures of GSK-3β protein and protein complexes | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-02-23 | — | — | US | claimed |
| EP-2082743-A2 | Inhibitors of GSK-3 and crystal structures of GSK-3beta protein and protein complexes | Vertex Pharmaceuticals Incorporated (US) | 2009-07-29 | — | — | EP | claimed |
| US-20080262205-A1 | Inhibitors of GSK-3 and crystal structures of GSK-3beta protein and protein complexes | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-10-23 | — | — | US | claimed |
| EP-1435957-A4 | INHIBITORS OF GSK-3 AND CRYSTAL STRUCTURES OF GSK-3BETA PROTEIN AND PROTEIN COMPLEXES | VERTEX PHARMA (US) | 2005-04-13 | — | — | EP | claimed |
| EP-1435957-A2 | INHIBITORS OF GSK-3 AND CRYSTAL STRUCTURES OF GSK-3BETA PROTEIN AND PROTEIN COMPLEXES | Vertex Pharmaceuticals Incorporated (US) | 2004-07-14 | — | — | EP | claimed |
| US-20030125332-A1 | Inhibitors of GSK-3 and crystal structures of GSK-3 protein and protein complexes | VERTEX PHARMACEUTICALS INCORPORATED | 2003-07-03 | — | — | US | claimed |
| WO-2002088078-A2 | INHIBITORS OF GSK-3 AND CRYSTAL STRUCTURES OF GSK-3β PROTEIN AND PROTEIN COMPLEXES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-11-07 | — | — | WO | claimed |
| US-8633210-B2 | Triazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-21 | — | — | US | disclosed |
| US-8524720-B2 | Substituted N-(pyrazol-5-yl)-pyrrolo[3,2-D]pyrimidin-4-amine useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-03 | — | — | US | disclosed |
| US-8318467-B2 | Inhibitors of GSK-3 and crystal structures of GSK-3β protein and protein complexes | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-27 | — | — | US | disclosed |
| US-20120071657-A1 | TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-22 | — | — | US | disclosed |
| US-20110129896-A1 | INHIBITORS OF GSK-3 AND CRYSTAL STRUCTURES OF GSK-3Beta PROTEIN AND PROTEIN COMPLEXES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-02 | — | — | US | disclosed |
| US-7951820-B2 | Triazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-05-31 | — | — | US | disclosed |
| US-20030083327-A1 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-05-01 | — | — | US | disclosed |
| US-20030078166-A1 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-04-24 | — | — | US | disclosed |
| US-20030073687-A1 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-04-17 | — | — | US | disclosed |
| US-20030064981-A1 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-04-03 | — | — | US | disclosed |
| US-20030064982-A1 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-04-03 | — | — | US | disclosed |
| US-20030055044-A1 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-03-20 | — | — | US | disclosed |
| WO-2002088078-A2 | INHIBITORS OF GSK-3 AND CRYSTAL STRUCTURES OF GSK-3β PROTEIN AND PROTEIN COMPLEXES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064981-A1 | Pyrazole compounds useful as protein kinase inhibitors | AURKC, AURKA, GSK3A | GSK3B 4/4885AURKA 2/4885SRC 305/4885 |
| US-20030064982-A1 | Pyrazole compounds useful as protein kinase inhibitors | MAP3K20, CDK2, MAP2K2 | GSK3B 461/4885AURKA 191/4885SRC 234/4885 |
| US-20030083327-A1 | Pyrazole compounds useful as protein kinase inhibitors | AURKC, AURKA, GSK3B | GSK3B 3/4885AURKA 2/4885SRC 256/4885 |
| US-20120071657-A1 | TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | GSK3B, GSK3A, CDK19 | GSK3B 1/4885AURKA 8/4885SRC 208/4885 |
| US-20030055044-A1 | Pyrazole compounds useful as protein kinase inhibitors | AURKC, AURKA, GSK3B | GSK3B 3/4885AURKA 2/4885SRC 294/4885 |
| US-20030073687-A1 | Pyrazole compounds useful as protein kinase inhibitors | AURKC, AURKA, GSK3B | GSK3B 3/4885AURKA 2/4885SRC 427/4885 |
| US-20030125332-A1 | Inhibitors of GSK-3 and crystal structures of GSK-3 protein and protein complexes | GSK3B, GSK3A, GSKIP | GSK3B 1/4885AURKA 828/4885SRC 280/4885 |
| US-20030078166-A1 | Pyrazole compounds useful as protein kinase inhibitors | GSK3B, GSK3A, GSKIP | GSK3B 1/4885AURKA 255/4885SRC 423/4885 |
| US-20080262205-A1 | Inhibitors of GSK-3 and crystal structures of GSK-3beta protein and protein complexes | GSK3B, GSK3A, GSKIP | GSK3B 1/4885AURKA 1243/4885SRC 426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.